BioCentury | Apr 28, 2020
Finance

Merck’s adjusted revenue guidance shows product mix matters during COVID-19

Merck’s heavy reliance on hospital-administered products, vaccines and animal health has left it more exposed than its pharma peers to the commercial impacts of the COVID-19 pandemic. The company cut its 2020 revenue guidance by...
BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

BioCentury, like the biomedical innovation ecosystem it serves, is relentlessly focused on the future, but the turn of a decade is a good time to check in on the progress industry has made possible --...
BC Extra | Oct 4, 2019
Company News

Icosavax’s self-assembling vaccine platform

Icosavax believes its computationally designed virus-like particles will open the clinically validated vaccine modality to a broader range of infectious diseases. The company expects its $51 million series A round, announced Thursday, to carry its...
BC Extra | Sep 27, 2019
Politics & Policy

China unveils three-year plan for cancer prevention, control

China’s 2019-22 cancer prevention and control plan broadly outlines measures the country plans to take to standardize screening and treatment, improve access to cancer drugs and accelerate review of HPV vaccines. The plan, released Monday,...
BC Extra | Jun 28, 2019
Company News

June 27 Company Quick Takes: Zogenix soars; plus Gardasil, Darzalex, Soliris and more

Zogenix shares surge after agreement to resubmit Fintepla NDA  Zogenix Inc. (NASDAQ:ZGNX) closed up $8.24 (21%) to $47.65 on Thursday after the company announced it had reached an agreement with FDA to resubmit its NDA...
BC Extra | Mar 1, 2019
Company News

Ex-Merck China R&D head joins Ascletis as CMO

Antiviral and cancer company Ascletis Pharma Inc. (HKSE:1672) hired Zhengqing Li as CMO and president of R&D Greater China. He was global VP of MSD China and general manager of the Merck & Co. Inc....
BC Week In Review | Jun 1, 2018
Company News

Chinese investors launch HPV JV

Shanghai Institute of Biological Products Co. Ltd. (Shanghai, China), 6 Dimensions Capital and Renxian Bioscience Co. Ltd. launched a JV -- Shanghai Zhicheng Bioscience Co. Ltd. -- to develop quadrivalent HPV vaccines in China. The...
BC Extra | May 25, 2018
Company News

Chinese investors launch HPV JV

Shanghai Institute of Biological Products Co. Ltd. (Shanghai, China), 6 Dimensions Capital and Renxian Bioscience Co. Ltd. launched a JV -- Shanghai Zhicheng Bioscience Co. Ltd. -- to develop quadrivalent HPV vaccines in China. The...
BioCentury | Sep 7, 2017
Strategy

What if you build, but they don’t come

Vaccination is widely considered one of the greatest medical achievements of modern civilization. Diseases that were commonplace less than a generation ago, such as polio, smallpox and diphtheria, are now increasingly rare because of vaccines....
BC Extra | Mar 9, 2016
Company News

Merck, Sanofi ending European vaccines JV

Merck & Co. Inc. (NYSE:MRK) and the Sanofi Pasteur S.A. vaccines unit of Sanofi (Euronext:SAN; NYSE:SNY) mutually agreed to end their European vaccines joint venture, Sanofi Pasteur MSD. The 50/50 JV was created in 1994....
Items per page:
1 - 10 of 209